Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNAECP)

Drug Name

SR-147778 Drug Info

Synonyms

Surinabant; SR-147778; UNII-SF8R9VCB0X; 288104-79-0; SR147778; SR 147778; SF8R9VCB0X; CHEMBL189676; Surinabant [INN]; DSSTox_CID_27357; DSSTox_RID_82293; DSSTox_GSID_47357; SCHEMBL675894; GTPL9233; DTXSID2047357; CHEBI:125484; ZINC1549068; Tox21_300239; BDBM50171290; DB13070; NCGC00254070-01; NCGC00247959-01; 5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide; LS-193786; FT-0766481; CAS-288104-79-0; BRD-K09557221-001-01-6

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Phase 2	[1]

Cross-matching ID

PubChem CID: 9849616
ChEBI ID: CHEBI:125484
CAS Number: CAS 288104-79-0
TTD Drug ID: DMNAECP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[3]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[4]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[5]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[6]
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[7]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[8]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[9]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[10]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[11]
V-24343	DMJSX9N	Type-2 diabetes	5A11	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00239174) A Multicenter Study to Evaluate the Efficacy and Safety of of Four Doses of SR147778 in Obese Patients. U.S. National Institutes of Health.
2	Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
3	Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
4	Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
5	Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
6	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
7	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
8	Clinical pipeline report, company report or official report of AstraZeneca (2009).
9	Company report (Gwpharm)
10	Clinical pipeline report, company report or official report of Bird Rock Bio.
11	Clinical pipeline report, company report or official report of Affimed Therapeutics.
12	Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65.